

## References

### X-5020

1. Blue Cross and Blue Shield Association Technology Evaluation Center (TEC). PET myocardial perfusion imaging for the detection of coronary artery disease clinical assessment. TEC Assessments. 1995;Volume 10:Tab 21.
2. Diamond GA, Forrester JS, Hirsch M, et al. Application of conditional probability analysis to the clinical diagnosis of coronary artery disease. *J Clin Invest.* May 1980; 65(5): 1210-21. PMID 6767741
3. Waller AH, Blankstein R, Kwong RY, et al. Myocardial blood flow quantification for evaluation of coronary artery disease by positron emission tomography, cardiac magnetic resonance imaging, and computed tomography. *Curr Cardiol Rep.* May 2014; 16(5): 483. PMID 24718671
4. Akaike G, Itani M, Shah H, et al. PET/CT in the Diagnosis and Workup of Sarcoidosis: Focus on Atypical Manifestations. *Radiographics.* Sep-Oct 2018; 38(5): 1536-1549. PMID 30118393
5. Food and Drug Administration (FDA). PET drugs - current good manufacturing practice (CGMP). 2009; <https://www.fda.gov/downloads/drugs/guidances/ucm070306.pdf>. Accessed July 28, 2021.
6. Food and Drug Administration (FDA). PET drugs - current good manufacturing practice (CGMP) (small entity compliance guide). 2011; <https://www.fda.gov/downloads/drugs/guidancecompliance/regulatoryinformation/guidances/ucm266640.pdf>. Accessed July 27, 2021.
7. Food and Drug Administration (FDA). Guidance: Investigational New Drug Applications for Positron Emission Tomography (PET) Drugs. 2012; <https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM291573.pdf>. Accessed July 26, 2021.
8. Beanlands RS, Chow BJ, Dick A, et al. CCS/CAR/CANM/CNCS/CanSCMR joint position statement on advanced noninvasive cardiac imaging using positron emission tomography, magnetic resonance imaging and multidetector computed tomographic angiography in the diagnosis and evaluation of ischemic heart disease--executive summary. *Can J Cardiol.* Feb 2007; 23(2): 107-19. PMID 17311116
9. Xu J, Cai F, Geng C, et al. Diagnostic Performance of CMR, SPECT, and PET Imaging for the Identification of Coronary Artery Disease: A Meta-Analysis. *Front Cardiovasc Med.* 2021; 8: 621389. PMID 34026862
10. Knuuti J, Ballo H, Juarez-Orozco LE, et al. The performance of non-invasive tests to rule-in and rule-out significant coronary artery stenosis in patients with

- stable angina: a meta-analysis focused on post-test disease probability. *Eur Heart J*. Sep 14 2018; 39(35): 3322-3330. PMID 29850808
11. Dai N, Zhang X, Zhang Y, et al. Enhanced diagnostic utility achieved by myocardial blood analysis: A meta-analysis of noninvasive cardiac imaging in the detection of functional coronary artery disease. *Int J Cardiol*. Oct 15 2016; 221: 665-73. PMID 27423088
  12. Takx RA, Blomberg BA, El Aidi H, et al. Diagnostic accuracy of stress myocardial perfusion imaging compared to invasive coronary angiography with fractional flow reserve meta-analysis. *Circ Cardiovasc Imaging*. Jan 2015; 8(1). PMID 25596143
  13. Bateman TM, Heller GV, McGhie AI, et al. Diagnostic accuracy of rest/stress ECG-gated Rb-82 myocardial perfusion PET: comparison with ECG-gated Tc-99m sestamibi SPECT. *J Nucl Cardiol*. Jan-Feb 2006; 13(1): 24-33. PMID 16464714
  14. Chen A, Wang H, Fan B, et al. Prognostic value of normal positron emission tomography myocardial perfusion imaging in patients with known or suspected coronary artery disease: a meta-analysis. *Br J Radiol*. Jun 2017; 90(1074): 20160702. PMID 28306335
  15. Smulders MW, Jaarsma C, Nelemans PJ, et al. Comparison of the prognostic value of negative non-invasive cardiac investigations in patients with suspected or known coronary artery disease-a meta-analysis. *Eur Heart J Cardiovasc Imaging*. Sep 01 2017; 18(9): 980-987. PMID 28329376
  16. Knesaurek K, Machac J. Comparison of 18F SPECT with PET in myocardial imaging: a realistic thorax-cardiac phantom study. *BMC Nucl Med*. Oct 31 2006; 6: 5. PMID 17076890
  17. Slart RH, Bax JJ, de Boer J, et al. Comparison of 99mTc-sestamibi/18FDG DISA SPECT with PET for the detection of viability in patients with coronary artery disease and left ventricular dysfunction. *Eur J Nucl Med Mol Imaging*. Aug 2005; 32(8): 972-9. PMID 15824927
  18. Beanlands RS, Nichol G, Huszti E, et al. F-18-fluorodeoxyglucose positron emission tomography imaging-assisted management of patients with severe left ventricular dysfunction and suspected coronary disease: a randomized, controlled trial (PARR-2). *J Am Coll Cardiol*. Nov 13 2007; 50(20): 2002-12. PMID 17996568
  19. Mc Ardle B, Shukla T, Nichol G, et al. Long-Term Follow-Up of Outcomes With F-18-Fluorodeoxyglucose Positron Emission Tomography Imaging-Assisted Management of Patients With Severe Left Ventricular Dysfunction Secondary to Coronary Disease. *Circ Cardiovasc Imaging*. Sep 2016; 9(9). PMID 27609816
  20. Siebelink HM, Blanksma PK, Crijns HJ, et al. No difference in cardiac event-free survival between positron emission tomography-guided and single-photon

- emission computed tomography-guided patient management: a prospective, randomized comparison of patients with suspicion of jeopardized myocardium. *J Am Coll Cardiol*. Jan 2001; 37(1): 81-8. PMID 11153777
21. Srivatsava MK, Indirani M, Sathyamurthy I, et al. Role of PET-CT in the assessment of myocardial viability in patients with left ventricular dysfunction. *Indian Heart J*. Sep 2016; 68(5): 693-699. PMID 27773409
  22. Bateman TM, Heller GV, Beanlands R, et al. Practical guide for interpreting and reporting cardiac PET measurements of myocardial blood flow: an Information Statement from the American Society of Nuclear Cardiology, and the Society of Nuclear Medicine and Molecular Imaging. *J Nucl Med*. Mar 31 2021. PMID 33789935
  23. Herzog BA, Husmann L, Valenta I, et al. Long-term prognostic value of <sup>13</sup>N-ammonia myocardial perfusion positron emission tomography added value of coronary flow reserve. *J Am Coll Cardiol*. Jul 07 2009; 54(2): 150-6. PMID 19573732
  24. Schindler TH, Schelbert HR, Quercioli A, et al. Cardiac PET imaging for the detection and monitoring of coronary artery disease and microvascular health. *JACC Cardiovasc Imaging*. Jun 2010; 3(6): 623-40. PMID 20541718
  25. Beanlands RS, Ziadi MC, Williams K. Quantification of myocardial flow reserve using positron emission imaging the journey to clinical use. *J Am Coll Cardiol*. Jul 07 2009; 54(2): 157-9. PMID 19573733
  26. Gould KL, Johnson NP, Bateman TM, et al. Anatomic versus physiologic assessment of coronary artery disease. Role of coronary flow reserve, fractional flow reserve, and positron emission tomography imaging in revascularization decision-making. *J Am Coll Cardiol*. Oct 29 2013; 62(18): 1639-1653. PMID 23954338
  27. Green R, Cantoni V, Acampa W, et al. Prognostic value of coronary flow reserve in patients with suspected or known coronary artery disease referred to PET myocardial perfusion imaging: A meta-analysis. *J Nucl Cardiol*. Jun 2021; 28(3): 904-918. PMID 31875285
  28. Juarez-Orozco LE, Tio RA, Alexanderson E, et al. Quantitative myocardial perfusion evaluation with positron emission tomography and the risk of cardiovascular events in patients with coronary artery disease: a systematic review of prognostic studies. *Eur Heart J Cardiovasc Imaging*. Oct 01 2018; 19(10): 1179-1187. PMID 29293983
  29. Tio RA, Dabeshlim A, Siebelink HM, et al. Comparison between the prognostic value of left ventricular function and myocardial perfusion reserve in patients with ischemic heart disease. *J Nucl Med*. Feb 2009; 50(2): 214-9. PMID 19164219
  30. Ziadi MC, Dekemp RA, Williams KA, et al. Impaired myocardial flow reserve on rubidium-82 positron emission tomography imaging predicts adverse

- outcomes in patients assessed for myocardial ischemia. *J Am Coll Cardiol*. Aug 09 2011; 58(7): 740-8. PMID 21816311
31. Fukushima K, Javadi MS, Higuchi T, et al. Prediction of short-term cardiovascular events using quantification of global myocardial flow reserve in patients referred for clinical <sup>82</sup>Rb PET perfusion imaging. *J Nucl Med*. May 2011; 52(5): 726-32. PMID 21498538
  32. Slart RH, Zeebregts CJ, Hillege HL, et al. Myocardial perfusion reserve after a PET-driven revascularization procedure: a strong prognostic factor. *J Nucl Med*. Jun 2011; 52(6): 873-9. PMID 21571798
  33. Farhad H, Dunet V, Bachelard K, et al. Added prognostic value of myocardial blood flow quantitation in rubidium-82 positron emission tomography imaging. *Eur Heart J Cardiovasc Imaging*. Dec 2013; 14(12): 1203-10. PMID 23660750
  34. Maaniitty T, Stenstrom I, Bax JJ, et al. Prognostic Value of Coronary CT Angiography With Selective PET Perfusion Imaging in Coronary Artery Disease. *JACC Cardiovasc Imaging*. Nov 2017; 10(11): 1361-1370. PMID 28528146
  35. Gupta A, Taqueti VR, van de Hoef TP, et al. Integrated Noninvasive Physiological Assessment of Coronary Circulatory Function and Impact on Cardiovascular Mortality in Patients With Stable Coronary Artery Disease. *Circulation*. Dec 12 2017; 136(24): 2325-2336. PMID 28864442
  36. Murthy VL, Naya M, Foster CR, et al. Improved cardiac risk assessment with noninvasive measures of coronary flow reserve. *Circulation*. Nov 15 2011; 124(20): 2215-24. PMID 22007073
  37. Taqueti VR, Hachamovitch R, Murthy VL, et al. Global coronary flow reserve is associated with adverse cardiovascular events independently of luminal angiographic severity and modifies the effect of early revascularization. *Circulation*. Jan 06 2015; 131(1): 19-27. PMID 25400060
  38. Murthy VL, Naya M, Taqueti VR, et al. Effects of sex on coronary microvascular dysfunction and cardiac outcomes. *Circulation*. Jun 17 2014; 129(24): 2518-27. PMID 24787469
  39. Majmudar MD, Murthy VL, Shah RV, et al. Quantification of coronary flow reserve in patients with ischaemic and non-ischaemic cardiomyopathy and its association with clinical outcomes. *Eur Heart J Cardiovasc Imaging*. Aug 2015; 16(8): 900-9. PMID 25719181
  40. Taqueti VR, Everett BM, Murthy VL, et al. Interaction of impaired coronary flow reserve and cardiomyocyte injury on adverse cardiovascular outcomes in patients without overt coronary artery disease. *Circulation*. Feb 10 2015; 131(6): 528-35. PMID 25480813
  41. Assante R, Acampa W, Zampella E, et al. Prognostic value of atherosclerotic burden and coronary vascular function in patients with suspected coronary

- artery disease. *Eur J Nucl Med Mol Imaging*. Dec 2017; 44(13): 2290-2298. PMID 28815291
42. Taqueti VR, Solomon SD, Shah AM, et al. Coronary microvascular dysfunction and future risk of heart failure with preserved ejection fraction. *Eur Heart J*. Mar 07 2018; 39(10): 840-849. PMID 29293969
  43. Gebhard C, Fiechter M, Herzog BA, et al. Sex differences in the long-term prognostic value of 13 N-ammonia myocardial perfusion positron emission tomography. *Eur J Nucl Med Mol Imaging*. Oct 2018; 45(11): 1964-1974. PMID 29779046
  44. Gould KL, Kitkungvan D, Johnson NP, et al. Mortality Prediction by Quantitative PET Perfusion Expressed as Coronary Flow Capacity With and Without Revascularization. *JACC Cardiovasc Imaging*. May 2021; 14(5): 1020-1034. PMID 33221205
  45. Patel KK, Spertus JA, Chan PS, et al. Myocardial blood flow reserve assessed by positron emission tomography myocardial perfusion imaging identifies patients with a survival benefit from early revascularization. *Eur Heart J*. Feb 01 2020; 41(6): 759-768. PMID 31228200
  46. Crouser ED, Maier LA, Wilson KC, et al. Diagnosis and Detection of Sarcoidosis. An Official American Thoracic Society Clinical Practice Guideline. *Am J Respir Crit Care Med*. Apr 15 2020; 201(8): e26-e51. PMID 32293205
  47. Chareonthaitawee P, Beanlands RS, Chen W, et al. Joint SNMMI-ASNC Expert Consensus Document on the Role of 18 F-FDG PET/CT in Cardiac Sarcoid Detection and Therapy Monitoring. *J Nucl Med*. Aug 2017; 58(8): 1341-1353. PMID 28765228
  48. Kim SJ, Pak K, Kim K. Diagnostic performance of F-18 FDG PET for detection of cardiac sarcoidosis; A systematic review and meta-analysis. *J Nucl Cardiol*. Dec 2020; 27(6): 2103-2115. PMID 30603894
  49. Wicks EC, Menezes LJ, Barnes A, et al. Diagnostic accuracy and prognostic value of simultaneous hybrid 18F-fluorodeoxyglucose positron emission tomography/magnetic resonance imaging in cardiac sarcoidosis. *Eur Heart J Cardiovasc Imaging*. Jul 01 2018; 19(7): 757-767. PMID 29319785
  50. Lapa C, Reiter T, Kircher M, et al. Somatostatin receptor based PET/CT in patients with the suspicion of cardiac sarcoidosis: an initial comparison to cardiac MRI. *Oncotarget*. Nov 22 2016; 7(47): 77807-77814. PMID 27780922
  51. Dilsizian V, Bacharach SL, Beanlands RS, et al. ASNC imaging guidelines/SNMMI procedure standard for positron emission tomography (PET) nuclear cardiology procedures. *J Nucl Cardiol*. Oct 2016; 23(5): 1187-1226. PMID 27392702
  52. Murthy VL, Bateman TM, Beanlands RS, et al. Clinical Quantification of Myocardial Blood Flow Using PET: Joint Position Paper of the SNMMI

- Cardiovascular Council and the ASNC. J Nucl Med. Feb 2018; 59(2): 273-293. PMID 29242396
53. Hendel RC, Berman DS, Di Carli MF, et al. ACCF/ASNC/ACR/AHA/ASE/SCCT/SCMR/SNM 2009 Appropriate Use Criteria for Cardiac Radionuclide Imaging: A Report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, the American Society of Nuclear Cardiology, the American College of Radiology, the American Heart Association, the American Society of Echocardiography, the Society of Cardiovascular Computed Tomography, the Society for Cardiovascular Magnetic Resonance, and the Society of Nuclear Medicine. J Am Coll Cardiol. Jun 09 2009; 53(23): 2201-29. PMID 19497454
54. American College of Radiology (ACR). ACR Appropriateness Criteria: Chronic Chest Pain -- High Probability of Coronary Artery Disease. 2016; <https://acsearch.acr.org/list>. Accessed July 25, 2021.
55. Akers SR, Panchal V, Ho VB, et al. ACR Appropriateness Criteria (R) Chronic Chest Pain-High Probability of Coronary Artery Disease. J Am Coll Radiol. May 2017; 14(5S): S71-S80. PMID 28473096
56. American College of Radiology (ACR). ACR Appropriateness Criteria: Chronic Chest Pain - Noncardiac Etiology Unlikely: Low to Intermediate Probability of Coronary Artery Disease. 2018; <https://acsearch.acr.org/list>. Accessed July 28, 2021.
57. American College of Radiology (ACR). ACR Appropriateness Criteria: Acute Nonspecific Chest Pain -- Low Probability of Coronary Artery Disease. 2020; <https://acsearch.acr.org/list>. Accessed July 26, 2021.
58. American College of Radiology (ACR). ACR Appropriateness Criteria: Asymptomatic Patient at Risk for Coronary Artery Disease. 2020; <https://acsearch.acr.org/list>. Accessed July 27, 2021.
59. Schindler TH, Bateman TM, Berman DS, et al. Appropriate Use Criteria for PET Myocardial Perfusion Imaging. J Nucl Med. Aug 2020; 61(8): 1221-1265. PMID 32747510
60. Centers for Medicare & Medicaid Services (CMS). Coverage and Related Claims Processing Requirements for Positron Emission Tomography (PET) Scans for Breast Cancer and Revised Coverage Conditions for Myocardial Viability. Transmittal AB-02-065. 2002; <https://www.cms.gov/medicare-coverage-database/details/ncd-details.aspx?NCID=211&ncdver=5&bc=AAAAEAAAQAA&>. Accessed July 28, 2021.